脂质体
卡铂
纳米载体
治疗指标
材料科学
药物输送
药理学
癌症研究
生物医学工程
化疗
医学
纳米技术
内科学
药品
顺铂
作者
Paul Cressey,Maral Amrahli,Po‐Wah So,Wladyslaw Gedroyc,Michael Wright,Maya Thanou
出处
期刊:Biomaterials
[Elsevier BV]
日期:2021-03-18
卷期号:271: 120758-120758
被引量:35
标识
DOI:10.1016/j.biomaterials.2021.120758
摘要
Triggerable nanocarriers have the potential to significantly improve the therapeutic index of existing anticancer agents. They allow for highly localised delivery and release of therapeutic cargos, reducing off-target toxicity and increasing anti-tumour activity. Liposomes may be engineered to respond to an externally applied stimulus such as focused ultrasound (FUS). Here, we report the first co-delivery of SN-38 (irinotecan's super-active metabolite) and carboplatin, using an MRI-visible thermosensitive liposome (iTSL). MR contrast enhancement was achieved by the incorporation of a gadolinium lipid conjugate in the liposome bilayer along with a dye-labelled lipid for near infrared fluorescence bioimaging. The resulting iTSL were successfully loaded with SN-38 in the lipid bilayer and carboplatin in the aqueous core - allowing co-delivery of both. The iTSL demonstrated both thermosensitivity and MR-imageability. In addition, they showed effective local targeted co-delivery of carboplatin and SN-38 after triggered release with brief FUS treatments. A single dosage induced significant improvement of anti-tumour activity (over either the free drugs or the iTSL without FUS-activation) in triple negative breast cancer xenografts tumours in mice.
科研通智能强力驱动
Strongly Powered by AbleSci AI